Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Boston Scientific Corporation Stories

2014-01-06 08:26:55

NATICK, Mass., Jan. 6, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the appointment of Craig Thompson, M.D., as senior vice president and chief medical officer, Interventional Cardiology, effective immediately. Dr. Thompson, a global leader in complex cardiac interventions, will play a key role in driving the development of innovative medical solutions within the Boston Scientific Interventional Cardiology business. (Photo:...

2014-01-02 08:23:13

NATICK, Mass., Jan. 2, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 32(nd) Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in San Francisco. Mike Mahoney, president and chief executive officer, will make a presentation about the company beginning at approximately 9:00 a.m. PT. Following the presentation, Dan Brennan, executive vice president and chief financial officer, and Keith Dawkins, M.D., executive...

2013-12-17 08:29:25

NATICK, Mass., Dec. 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN(TM) X4, DYNAGEN(TM) X4, and INOGEN(TM) X4 cardiac resynchronization therapy defibrillators (CRT-Ds), a suite of ACUITY(TM) X4 quadripolar LV leads and the ACUITY(TM) PRO lead delivery system. The company's latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient...

2013-12-16 08:26:31

NATICK, Mass., Dec. 16, 2013 /PRNewswire/ -- The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected David Roux as a Director. The appointment of Mr. Roux will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from ten to eleven. The increase in the number of directors and Mr. Roux's appointment to the Board are both effective January 1, 2014. Mr. Roux is a co-founder and Senior Director of...

2013-12-11 20:21:53

NATICK, Mass., Dec. 11, 2013 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the WATCHMAN Left Atrial Appendage Closure device outweigh the risks. The FDA Panel was further asked if there is reasonable assurance that the device is safe, the Panel voted Yes: 13, No: 1. On the question of reasonable assurance of efficacy, the...

2013-12-06 08:24:50

New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain NATICK, Mass., Dec. 6, 2013 /PRNewswire/ -- New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra(TM) Spinal Cord Stimulator (SCS) System demonstrate the device provided highly significant pain relief three months after implantation. Results were presented at the North...

2013-12-06 08:24:10

NATICK, Mass. and PARSIPPANY, N.J., Dec. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional...

2013-11-25 08:28:08

Advanced Stent Technology to Launch Immediately in the United States NATICK, Mass., Nov. 25, 2013 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES). The technology is available immediately...

2013-11-22 08:23:57

NATICK, Mass., Nov. 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25(th) Annual Piper Jaffray Healthcare Conference on December 3 in New York. Mike Mahoney, president and chief executive officer, and Dan Brennan, senior vice president and corporate controller, will participate in a 30-minute question and answer session regarding the company on Tuesday, December 3, at approximately 8:30 a.m. ET. A live webcast of the question...

2013-11-21 16:27:21

NATICK, Mass., Nov. 21, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective December 2, 2013. Lisa has more than 20 years of diverse financial and healthcare industry experience, including extensive knowledge of the medical technology industry. Lisa previously served as senior director, investor relations and corporate development at Abiomed, Inc., a medical technology...